NCT03157089View on ClinicalTrials.gov

Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 2, 2017

Primary Completion Date

January 13, 2020

Study Completion Date

January 13, 2020

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Afatinib

Film-coated tablet

DRUG

pembrolizumab

Solution for infusion

Trial Locations (13)

13015

HOP Nord, Marseille

14033

HOP Côte de Nacre, Caen

28041

Hospital Universitario 12 de Octubre, Madrid

34098

Istanbul Universitesi Cerrahpasa Tip Fakultesi, Istanbul

35016

Complejo Hospitalario Universitario Insular - Materno Infantil, Las Palmas de Gran Canaria

40503

Baptist Health Medical Group, Lexington

44093

HOP Nord Laënnec, Nantes

50009

Hospital Clínico Universitario Lozano Blesa, Zaragoza

72037

HOP Le Mans, Le Mans

03722

Severance Hospital, Seoul

05505

Asan Medical Center, Seoul

08035

Hospital Vall d'Hebron, Barcelona

06230

Hacettepe Universitesi Tip Fakultesi, Onkoloji ABD, Ankara

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03157089 - Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung | Biotech Hunter | Biotech Hunter